Antioxidant, Anti-acetylcholinesterase, and Anti-amyloid-β Peptide Aggregations of Hispolon and Its Analogs in Vitro and Improved Learning and Memory Functions in Scopolamine-induced ICR Mice

Overview

Journal Bot Stud

Specialty Biology

Date 2024 Dec 18

PMID 39692936

Authors

Chang-Hang Yang

Cai-Wei Li

Yi-Yan Sie

Liang-Chieh Chen

Yu-Hsiang Yuan

Wen-Chi Hou

Affiliations

Soon will be listed here.

Abstract

Background: Hispolon, one of bioactive phenolic compounds from a medicinal mushroom of sang-huang (Phellinus linteus) has been reported to exhibit anticancer and anti-inflammatory activities. The Alzheimer's disease (AD) is ranked one of the top ten leading causes of death worldwide. Little is known about the effects of hispolon on delaying AD progression.

Results: The hispolon (No.1) and its six structural analogs (No.2 to No.7) were assayed by antioxidant, anti-acetylcholinesterase activities and anti-amyloid-β-peptide aggregations. The No.1, No.6, and No.7 were selected for further molecular docking with acetylcholinesterase and core fragments of amyloid-β-peptide, and also showed capacities to recover cell viabilities in methylglyoxal-treated SH-SY5Y cells and also to enhance neurite outgrowths in PC12 cells. The daily pre-treatments of No.1, No.6, and No.7 for 10-days (40 mg/kg/day) showed to improve learning dysfunctions in scopolamine-induced ICR mice by passive avoidance tests.

Conclusion: The hispolon in the fungus sang-huang might be beneficial to develop functional foods or as lead compounds for treating degenerative disorders.

References

Ravindran J, Subbaraju G, Ramani M, Sung B, Aggarwal B . Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochem Pharmacol. 2010; 79(11):1658-66. PMC: 2846970. DOI: 10.1016/j.bcp.2010.01.033. View

Zhang L, Cao K, Xie J, Liang X, Gong H, Luo Q . Aβ and ROS dual-targeted multifunctional nanocomposite for combination therapy of Alzheimer's disease. J Nanobiotechnology. 2024; 22(1):278. PMC: 11112798. DOI: 10.1186/s12951-024-02543-z. View

Kikuchi S, Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N . Glycation--a sweet tempter for neuronal death. Brain Res Brain Res Rev. 2003; 41(2-3):306-23. DOI: 10.1016/s0165-0173(02)00273-4. View

Allaman I, Belanger M, Magistretti P . Methylglyoxal, the dark side of glycolysis. Front Neurosci. 2015; 9:23. PMC: 4321437. DOI: 10.3389/fnins.2015.00023. View

Gella A, Durany N . Oxidative stress in Alzheimer disease. Cell Adh Migr. 2009; 3(1):88-93. PMC: 2675154. DOI: 10.4161/cam.3.1.7402. View

van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M . Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022; 388(1):9-21. DOI: 10.1056/NEJMoa2212948. View

Wang C, Lin S, Cheng H, Hou W . Pro-oxidant and cytotoxic activities of atractylenolide I in human promyeloleukemic HL-60 cells. Food Chem Toxicol. 2006; 44(8):1308-15. DOI: 10.1016/j.fct.2006.02.008. View

McGleenon B, Dynan K, Passmore A . Acetylcholinesterase inhibitors in Alzheimer's disease. Br J Clin Pharmacol. 1999; 48(4):471-80. PMC: 2014378. DOI: 10.1046/j.1365-2125.1999.00026.x. View

Tarawneh R, Holtzman D . The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012; 2(5):a006148. PMC: 3331682. DOI: 10.1101/cshperspect.a006148. View

10.

Jack Jr C, Lowe V, Weigand S, Wiste H, Senjem M, Knopman D . Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; 132(Pt 5):1355-65. PMC: 2677798. DOI: 10.1093/brain/awp062. View

11.

Craig L, Hong N, McDonald R . Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev. 2011; 35(6):1397-409. DOI: 10.1016/j.neubiorev.2011.03.001. View

12.

Chen L, Wang C, Lee Y, Sie Y, Chang C, Hou W . Vitisin A, a Resveratrol Tetramer, Improves Scopolamine-Induced Impaired Learning and Memory Functions in Amnesiac ICR Mice. Biomedicines. 2022; 10(2). PMC: 8869728. DOI: 10.3390/biomedicines10020273. View

13.

Weinreb O, Amit T, Bar-Am O, Youdim M . Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease. Br J Pharmacol. 2015; 173(13):2080-94. PMC: 4908201. DOI: 10.1111/bph.13318. View

14.

Chang H, Sheu M, Yang C, Lu T, Chang Y, Peng W . Analgesic effects and the mechanisms of anti-inflammation of hispolon in mice. Evid Based Complement Alternat Med. 2009; 2011:478246. PMC: 3136186. DOI: 10.1093/ecam/nep027. View

15.

Liu Y, Lee C, Chen L, Lee T, Hsieh Y, Han C . Acetylcholinesterase inhibitory activity and neuroprotection in vitro, molecular docking, and improved learning and memory functions of demethylcurcumin in scopolamine-induced amnesia ICR mice. Food Funct. 2020; 11(3):2328-2338. DOI: 10.1039/c9fo02339a. View

16.

Kovalevich J, Langford D . Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013; 1078:9-21. PMC: 5127451. DOI: 10.1007/978-1-62703-640-5_2. View

17.

Cummings J, Leisgang Osse A, Cammann D, Powell J, Chen J . Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. BioDrugs. 2023; 38(1):5-22. PMC: 10789674. DOI: 10.1007/s40259-023-00633-2. View

18.

Arndt J, Qian F, Smith B, Quan C, Kilambi K, Bush M . Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018; 8(1):6412. PMC: 5913127. DOI: 10.1038/s41598-018-24501-0. View

19.

Perneczky R, Jessen F, Grimmer T, Levin J, Floel A, Peters O . Anti-amyloid antibody therapies in Alzheimer's disease. Brain. 2023; 146(3):842-849. DOI: 10.1093/brain/awad005. View

20.

Xu S, Choi R, Zhu K, Leung K, Guo A, Bi D . Isorhamnetin, A Flavonol Aglycone from Ginkgo biloba L., Induces Neuronal Differentiation of Cultured PC12 Cells: Potentiating the Effect of Nerve Growth Factor. Evid Based Complement Alternat Med. 2012; 2012:278273. PMC: 3385709. DOI: 10.1155/2012/278273. View